Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer

Ignacio Gil-Bazo^{1

2

3}

Affiliations

Editorial

Ignacio Gil-Bazo. Transl Lung Cancer Res. 2017 Dec.

. 2017 Dec;6(Suppl 1):S35-S38.

doi: 10.21037/tlcr.2017.11.01.

Ignacio Gil-Bazo^{1

2

3}

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K. Gulley JL, et al. Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub 2017 Mar 31. Lancet Oncol. 2017. PMID: 28373005 Free PMC article. Clinical Trial.

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. 10.1002/ijc.29210 - DOI - PubMed
1. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307-14. 10.1007/s00262-004-0593-x - DOI - PMC - PubMed
1. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11:14-20. 10.1038/ni.1794 - DOI - PubMed
1. Iafolla MA, Juergens RA. Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front Oncol 2017;7:67. 10.3389/fonc.2017.00067 - DOI - PMC - PubMed
1. Liu K, Tan S, Chai Y, et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res 2017;27:151-3. 10.1038/cr.2016.102 - DOI - PMC - PubMed